<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951505</url>
  </required_header>
  <id_info>
    <org_study_id>VNRX-5133-107</org_study_id>
    <nct_id>NCT04951505</nct_id>
  </id_info>
  <brief_title>Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy Subjects</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Venatorx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Venatorx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label study to assess the safety and intrapulmonary&#xD;
      pharmacokinetics of cefepime and taniborbactam in healthy adult male and female subjects.&#xD;
      Thirty subjects will receive a total of 6 doses of cefepime-taniborbactam (2 g cefepime/0.5g&#xD;
      taniborbactam) administered intravenously every 8 hours. Following the sixth dose of&#xD;
      cefepime-taniborbactam, subjects will be assigned to one of six bronchoscopy sampling times.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Actual">September 27, 2021</completion_date>
  <primary_completion_date type="Actual">September 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ELF Cmax</measure>
    <time_frame>0-8 hours after 6th dose</time_frame>
    <description>Maximum concentrations of cefepime and taniborbactam, determined directly from individual concentration-time data, in epithelial lining fluid (ELF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Day 1 - Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>cefepime-taniborbactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefepime-taniborbactam</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>cefepime-taniborbactam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults 18-55 years&#xD;
&#xD;
          2. Males or non-pregnant, non-lactating females&#xD;
&#xD;
          3. Body mass index (BMI): ≥18 kg/m2 and ≤32.0 kg/m2, weight &gt;50.0 kg.&#xD;
&#xD;
          4. Must have negative alcohol, drug, or tobacco use/test and no use of alcohol, caffeine&#xD;
             during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of current cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, autoimmune, hematologic, neoplastic, or neurological&#xD;
             disorders&#xD;
&#xD;
          2. History of drug allergy or hypersensitivity to penicillin, cephalosporin, or&#xD;
             beta-lactam antibacterial drug&#xD;
&#xD;
          3. Recent history of known or suspected Clostridioides difficile infection&#xD;
&#xD;
          4. Abnormal ECG or history of clinically significant abnormal rhythm disorder&#xD;
&#xD;
          5. Abnormal lab tests&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pulmonary Associates PA</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefepime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

